Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather than addressing the symptoms of a conditions. In particular, the article discusses how the complement system plays a key role in immune regulation and, as such, is an attractive target to address a range of diseases with an autoimmune component.
Originally published in European Pharmaceutical Contractor. Read the full article here.